Definium Hits Another Phase 3 Homerun with Psychedelic Sea Change for Anxiety on August 12, 2026 Definium Therapeutics Depressive disorder DT120 ODT Emerge trial Generalized Anxiety Disorder Hamilton Anxiety Rating Scale LSD therapy Panorama trial psychedelic therapy Voyage trial +
Definium's LSD Formula Produces Best Data Ever Seen in Pivotal Depression Trial, CEO Says on June 22, 2026 Definium Therapeutics Depressive disorder DT120 ODT Lysergic Acid Diethylamide MADRS score Major Depressive Disorder Montgomery-Åsberg Depression Rating Scale placebo-adjusted improvement remission rate +
Neumora to lay off about 35% of staff after navacaprant fails late-stage depression trials on June 15, 2026 35 Depressive disorder KOASTAL-2 KOASTAL-3 navacaprant Neumora Therapeutics +
Biohaven's BHV-7000 Ion Channel Drug Fails Phase 2 Trial in Major Depressive Disorder on January 02, 2026 BHV-7000 Biohaven Depressive disorder Kv7 activator psychiatric trials +
Neurocrine’s Phase 2 Depression Drug Fails Primary Endpoint in Major Takeda-Licensed Study on November 11, 2025 Biosciences Clinical Trials depression drug Depressive disorder drug licensing NBI-1070770 Neurocrine pharmaceutical setbacks Phase 2 Failure psychiatry pipeline Takeda +